KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme. PMID 40889900 · BMJ Open Gastroenterol · 2025-Aug-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes. PMID 40887579 · Cardiovasc Diabetol · 2025-Aug-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study). PMID 40887121 · BMJ Open · 2025-Aug-31 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. PMID 40950337 · J Gastrointest Oncol · 2025-Aug-30 This is a retrospective cohort study, not a randomized controlled trial. It does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay. PMID 40886427 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age. PMID 40763490 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study. PMID 40752250 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine. PMID 40749348 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older. PMID 40714528 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial. PMID 40714527 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial. PMID 40966617 · Age Ageing · 2025-Aug-29 The study is a randomized, placebo-controlled trial of a cocoa extract supplement, but it is not an oncology study. It focuses on inflammaging biomarkers in older adults, not on cancer outcomes. The primary endpoints are changes in biomarkers (hsCRP, IFN-γ, etc.), not time-to-event efficacy endpoints such as OS, PFS, or DFS. Therefore, it does not meet the eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Four-week remotely supervised aerobic exercise during the COVID-19 era: Exploring physical performance and psychosocial health in adults without COVID-19 living in rural settings. PMID 40898552 · Medicine (Baltimore) · 2025-Aug-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrated Model of Cancer Control for Early Detection and Treatment in Adolescents and Young Adults Living With HIV: Protocol for a Cluster Randomized Controlled Trial. PMID 40882199 · JMIR Res Protoc · 2025-Aug-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials. PMID 40877276 · Nat Commun · 2025-Aug-28 The record is a secondary analysis of heterogeneity in lung cancer screening effectiveness from two large RCTs. While it is a randomized human oncology study with results, it does not meet the core criteria: it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention, and it does not report a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) for such an intervention. The endpoint analyzed is screening effectiveness (mortality reduction), which is not a standard time-to-event endpoint for a drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma. PMID 40279508 · Blood · 2025-Aug-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. PMID 40894139 · medRxiv · 2025-Aug-27 The record describes a non-randomized, correlative/prospective trial without a drug intervention, lacking clear Phase III/IIIb or Phase II/III evidence for a randomized drug evaluation.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials. PMID 40866864 · BMC Cancer · 2025-Aug-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. PMID 40866060 · BMJ Open · 2025-Aug-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial. PMID 40859341 · BMC Med · 2025-Aug-26 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Community navigation intervention for social needs in patients with abnormal mammography: a randomized controlled trial study protocol. PMID 40859259 · BMC Public Health · 2025-Aug-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma. PMID 40859225 · BMC Cancer · 2025-Aug-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial. PMID 40858558 · Nat Commun · 2025-Aug-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial. PMID 40857715 · JMIR Res Protoc · 2025-Aug-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety of alisertib in the treatment of solid and hematological cancers: A systematic review and meta-analysis of randomized controlled trials. PMID 40856692 · J Oncol Pharm Pract · 2025-Aug-26 This is a systematic review and meta-analysis focused on safety outcomes (adverse events). It is not an original report of a single randomized trial, and it does not report a time-to-event efficacy endpoint (OS, PFS, etc.) as the primary or key secondary outcome.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. PMID 40554429 · Blood Adv · 2025-Aug-26 The trial is a randomized controlled trial in oncology (hematologic malignancies) with drug intervention and time-to-event endpoints. However, the phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, which is a required criterion for eligibility. Therefore, it cannot be confirmed as meeting all inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. PMID 40334072 · Blood Adv · 2025-Aug-26 The study meets the criteria for being an original, randomized, phase III oncology trial with a drug intervention. However, the primary reported efficacy endpoint (MMR) is a categorical response rate, not the required primary or key secondary time-to-event endpoint (e.g., OS, PFS). No time-to-event signal is present in the provided metadata.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Beyond Analgesia: Psychobiotics as an Adjunctive Approach to Pain Management in Gastrointestinal Oncology-A Post Hoc Analysis from the ProDeCa Study. PMID 40944142 · Nutrients · 2025-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial. PMID 40875502 · J Clin Psychiatry · 2025-Aug-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mini-laparotomy versus transrectal natural orifice specimen extraction for minimally invasive colorectal cancer surgery: study protocol for a randomized controlled trial (MINITR-NOSE trial, TCAR2514 protocol). PMID 40855494 · Trials · 2025-Aug-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. PMID 40855441 · Trials · 2025-Aug-25 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment. PMID 40855285 · BMC Cancer · 2025-Aug-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. PMID 40854810 · RMD Open · 2025-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Smartphone App-Guided Pulmonary Rehabilitation in Chronic Respiratory Diseases: Randomized Controlled Trial. PMID 40854157 · JMIR Mhealth Uhealth · 2025-Aug-25 The study is a randomized controlled trial of a smartphone app for pulmonary rehabilitation in chronic respiratory diseases, including some patients with lung cancer. However, it does not meet the eligibility criteria because it is not primarily an oncology trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint (OS, PFS, etc.) as its primary or key secondary outcome. The primary endpoint is 6-minute walk test distance.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. PMID 40853558 · Ann Surg · 2025-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Long-term oncological safety of robotic total gastrectomy for locally advanced proximal gastric cancer: a 5-year noninferiority comparison based on the FUGES-014 study]. PMID 40850834 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Aug-25 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Systematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU. PMID 40850913 · BMJ Open · 2025-Aug-24 This record is a protocol for a randomized trial without results. While it meets criteria for oncology, human subjects, randomization, and a time-to-event endpoint (overall survival as a secondary objective), it is ineligible because: 1) It is a protocol, not an original result report; 2) The intervention is a palliative care referral strategy, not a drug-containing intervention (no drug is named or described as part of the experimental arm); 3) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. PMID 40940844 · Cancers (Basel) · 2025-Aug-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Polypill and Riskometer to Prevent Stroke and Cognitive Impairment in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and Design. PMID 40875725 · Neuroepidemiology · 2025-Aug-23 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis. PMID 40849447 · BMC Cancer · 2025-Aug-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. PMID 40848059 · Cancer Chemother Pharmacol · 2025-Aug-23 The study is an exposure-response analysis of efficacy (MM response) and safety for asciminib in CML, referencing Phase III trials but not reporting a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. The primary/key secondary endpoints are MM response rates and safety incidences, which do not meet the time-to-event requirement for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of utilizing a hypertonic saline solution and mannitol to improve brain relaxation during craniotomy in patients with brain tumours: a prospective randomized controlled trial. PMID 40846709 · Sci Rep · 2025-Aug-22 The study is an oncology-related randomized trial comparing two drug interventions, but its primary efficacy endpoint is not a time-to-event outcome. Therefore, it does not meet the core requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. PMID 40834301 · N Engl J Med · 2025-Aug-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. PMID 40561369 · J Clin Oncol · 2025-Aug-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study. PMID 40474341 · Chin Med J (Engl) · 2025-Aug-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial. PMID 40829896 · BMJ · 2025-Aug-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial. PMID 40792599 · J Am Heart Assoc · 2025-Aug-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis. PMID 40826400 · BMC Cancer · 2025-Aug-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204). PMID 40826041 · BMC Cancer · 2025-Aug-18 The record describes a quality assurance sub-study for an ongoing Phase III trial, not the primary efficacy results. No time-to-event outcomes are reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical Trial. PMID 40824660 · JAMA Neurol · 2025-Aug-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial. PMID 40824573 · JAMA · 2025-Aug-18 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -